Abstract
BackgroundOsteoporosis is an important chronic disease, requiring prolonged treatment. Long-term efficacy and safety data are therefore of great importance. Denosumab (DMAb) is used in over 80 countries or administrative districts...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
